SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Houssiau Frederic)
 

Search: WFRF:(Houssiau Frederic) > (2015-2019) > Off-label use of ri...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005892naa a2200721 4500
001oai:lup.lub.lu.se:c24ba2fe-696d-4046-8a41-f2298da25d1c
003SwePub
008161006s2016 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:227651920
0247 a https://lup.lub.lu.se/record/c24ba2fe-696d-4046-8a41-f2298da25d1c2 URI
0247 a https://doi.org/10.1136/lupus-2016-0001632 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:2276519202 URI
040 a (SwePub)lud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a for2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Ryden-Aulin, Monicau Karolinska Institutet4 aut
2451 0a Off-label use of rituximab for systemic lupus erythematosus in Europe
264 c 2016-09-06
264 1b BMJ,c 2016
520 a Objectives: Rituximab (RTX) is a biological treatment used off-label in patients with systemic lupus erythematosus (SLE). This survey aimed to investigate the off-label use of RTX in Europe and compare the characteristics of patients receiving RTX with those receiving conventional therapy. Methods: Data on patients with SLE receiving RTX were taken from the International Registry for Biologics in SLE retrospective registry and complemented with data on patients with SLE treated with conventional therapy. For nationwide estimates of RTX use in patients with SLE, investigators were asked to provide data through case report forms (CRFs). Countries for which no data were submitted through CRFs, published literature and/or personal communication were used, and for European countries where no data were available, estimates were made on the assumption of similarities with neighbouring countries. Results: The estimated off-label use of RTX in Europe was 0.5%-1.5% of all patients with SLE. In comparison with patients with SLE on conventional therapy, patients treated with RTX had longer disease duration, higher disease activity and were more often treated with immunosuppressives. The most frequent organ manifestations for which either RTX or conventional therapy was initiated were lupus nephritis followed by musculoskeletal and haematological. The reason for treatment was, besides disease control, corticosteroid-sparing for patients treated with conventional therapy. Conclusions: RTX use for SLE in Europe is restrictive and appears to be used as a last resort in patients for whom other reasonable options have been exhausted.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Reumatologi och inflammation0 (SwePub)302102 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Rheumatology and Autoimmunity0 (SwePub)302102 hsv//eng
7001 a Boumpas, Dimitriosu National and Kapodistrian University of Athens4 aut
7001 a Bultink, Ireneu Amsterdam Rheumatology and Immunology Center4 aut
7001 a Rubio, Jose Luis Callejasu Hospital Clínico Universitario San Cecilio4 aut
7001 a Caminal-Montero, Luisu Asturias General Hospital4 aut
7001 a Castro, Antoniu Rovira i Virgili University (URV)4 aut
7001 a Ruiz, Agustín Colodrou Pasaje Nueva Victoria4 aut
7001 a Doria, Andreau University of Padova4 aut
7001 a Dorner, Thomasu Charité - University Medicine Berlin4 aut
7001 a Gonzalez-Echavarri, Cristinau University of the Basque Country4 aut
7001 a Gremese, Elisau Catholic University of the Sacred Heart, Rome4 aut
7001 a Houssiau, Frederic A.u Saint-Luc University Hospital4 aut
7001 a Huizinga, Tomu Leiden University Medical Centre4 aut
7001 a Inanc, Muratu Istanbul University4 aut
7001 a Isenberg, Davidu Royal Free Hospital4 aut
7001 a Iuliano, Annamariau Azienda Ospedaliera San Camillo Forlanini4 aut
7001 a Jacobsen, Sorenu University of Copenhagen4 aut
7001 a Jimenez-Alonso, Juanu Hospital Clínico Universitario San Cecilio4 aut
7001 a Kovacs, Laszlou University of Szeged4 aut
7001 a Mariette, Xavieru Center For Immunology Of Viral Infections And Autoimmune Diseases4 aut
7001 a Mosca, Martau University of Pisa4 aut
7001 a Nived, Olau Lund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital4 aut0 (Swepub:lu)reum-oni
7001 a Oristrell, Joaquimu Autonomous University of Barcelona4 aut
7001 a Ramos-Casals, Manuelu Institutd' Investigacions Biomèdiques August Pi iSunyer (IDIBAPS)4 aut
7001 a Rascon, Javier4 aut
7001 a Ruiz-Irastorza, Guillermou University of the Basque Country4 aut
7001 a Sáez-Comet, Luisu Miguel Servet University Hospital4 aut
7001 a Cervello, Gonzalo Salvadoru University and Polytechnic Hospital la Fe4 aut
7001 a Sebastiani, Gian Domenicou Azienda Ospedaliera San Camillo Forlanini4 aut
7001 a Squatrito, Danilou University of Florence4 aut
7001 a Szucs, Gabriellau University of Debrecen4 aut
7001 a Voskuyl, Alexandreu Amsterdam UMC - Vrije Universiteit Amsterdam4 aut
7001 a Van Vollenhoven, Ronaldu Karolinska Institutet4 aut
7102 a Karolinska Institutetb National and Kapodistrian University of Athens4 org
7730 t Lupus Science and Medicined : BMJg 3:1q 3:1x 2053-8790
8564 u http://dx.doi.org/10.1136/lupus-2016-000163x freey FULLTEXT
8564 u https://lupus.bmj.com/content/lupusscimed/3/1/e000163.full.pdf
8564 8u https://lup.lub.lu.se/record/c24ba2fe-696d-4046-8a41-f2298da25d1c
8564 8u https://doi.org/10.1136/lupus-2016-000163
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:227651920

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view